Filed with ASX · · 3 pages · English
This clearance allows for continuous EEG monitoring in adolescents, addressing a significant gap in access to necessary treatment for this vulnerable population. The Minder System provides a minimally invasive solution that captures and transmits EEG data wirelessly, enabling better monitoring and treatment decisions for young patients. The announcement highlights the importance of this development for improving the quality of life and treatment outcomes for adolescents with epilepsy.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Minder® System Cleared for Patients 12 -75 Years of Age Highlights: • The U.S. Food and Drug Administration (FDA) has cleared the Minder® System to include patients aged 12 years and older with drug-resistant epilepsy, broadening eligible access beyond the original clearance for patients 18...
